Joint pain. Stiffness. Fatigue. Muscle weakness. Women are told these are normal — part of aging, part of being female, part of something to manage rather than investigate.
They are part of a larger, recognizable pattern. One that has been hiding in plain sight — and is only now being named.
This isn’t new science. It’s long-standing knowledge buried beneath decades of research gaps, clinical bias, and a healthcare system built around male physiology.
The cost is cumulative. Women lose strength, mobility, and confidence in their own bodies — often without ever being told why.
For decades, women have been systematically underrepresented in the data that shapes healthcare. The result is predictable: delayed diagnoses, dismissed symptoms, and conditions like Menopause Musculoskeletal Syndrome — affecting an estimated 70% of women — remaining largely unrecognized.
When conditions go unnamed, they go unmanaged. Symptoms get addressed in isolation — osteoporosis at one appointment, muscle loss at another, joint pain attributed to aging at a third. No one connects the dots. That gap makes self-advocacy not optional — necessary.
Why This Gap Exists
MMS was formally named in 2024 — but the underlying biology has been present for decades, fragmented across separate appointments and separate diagnoses. No framework existed to connect them. That’s the first problem.
The second: research has historically centered male physiology. Women — particularly of childbearing age — were excluded from most clinical trials for much of the twentieth century, with meaningful inclusion only beginning in the 1990s. Hormone variability was considered too complex to study.
The pattern extended beyond physiology. Neurodevelopmental conditions like ADHD and autism were diagnosed almost exclusively in boys — because the criteria were built on how they present in boys. Women who internalized and masked were invisible in the data. Medications were dosed on male trial data for decades — Ambien’s recommended dose for women wasn’t corrected until 2013, after years of women experiencing adverse effects the original trials never captured.
The third: medical training still defaults to male norms. In textbooks, case studies, and clinical guidelines, the standard patient is male. When women present differently, symptoms are more likely to be misattributed, undertreated, or dismissed.
The fourth: primary care visits are short and there are no established guidelines for MMS. Reports of weakness, stiffness, and fatigue tend to produce symptom-based responses — yoga, stretching, anti-inflammatories — rather than systemic evaluation. Without a framework, clinicians lack both the language and the structure to address the bigger picture.
The fifth: menopause remains culturally uncomfortable. It is still framed as loss — of youth, relevance, sexual currency. That discomfort carries into clinical settings, where naming menopause directly can itself limit the conversation.
The sixth — and perhaps most clarifying: there is no profit motive. MMS, pelvic floor dysfunction, perimenopausal decline — these conditions don’t fit a single-drug solution. When treatment requires lifestyle change, strength work, and metabolic intervention rather than prescription, conditions receive less funding, less research, and less urgency. The healthcare system optimizes for what it can sell.
And yet GLP-1s — drugs originally developed for type 2 diabetes — are now being prescribed cosmetically for weight loss at scale, while the conditions eroding women’s strength and independence remain largely unaddressed in routine care.
Women Have Been Minimized—Because The System Was Never Designed For Us
Women’s symptoms are still more likely to be reframed as anxiety, stress, or normal aging. A persistent bias equates emotional expression with exaggeration — particularly when women describe pain, fatigue, or cognitive changes. The pattern is consistent: when the default is male, women don’t get answers. They get alternative explanations for why something must be wrong with them.
The consequences are not always slow. Women having heart attacks are more likely to be sent home from emergency rooms than men — their symptoms reframed as anxiety or stress rather than recognized as cardiac. The chest-clutching presentation medicine trained on is male. Women present with fatigue, nausea, jaw pain, back pain. When the template is wrong, the diagnosis is wrong — and in cardiac care, that delay kills. Stroke follows the same pattern — sudden confusion, vision changes, hiccups rather than classic one-sided weakness. Atypical means female. Atypical means missed.
The result is delayed diagnosis, fragmented care, and women who leave appointments doubting their own experience.
Conditions that disproportionately affect women — autoimmune disease, endometriosis, chronic fatigue, and now MMS — remain underfunded, under-researched, and widely misunderstood. This is not coincidence. It is the predictable outcome of a system built on data that largely excluded us.
This Is Changing—Because Women Are Demanding it
The naming of MMS in 2024 reflects a broader, patient-driven shift. Women are asking more informed questions, challenging what has been normalized, and demanding research that reflects their actual physiology. Too long offered vague reassurance or told to live with it — the research is beginning to catch up with the experience.
It gives language to a pattern millions of women have been living without explanation.
View and download the full MMS research article and download the MMS Discussion Guide. Bring it to your next appointment.
Know Your Numbers – Ask for These Tests
These labs and scans can help assess your musculoskeletal, metabolic, and inflammatory markers—giving you a clearer picture of what’s actually happening.
- DEXA scan – bone density and body composition (muscle vs. fat)
- Vitamin D levels – foundational for bone and immune health
- A1C + fasting insulin or glucose – early insulin resistance often precedes diagnosis
- High-sensitivity CRP or ESR – markers of chronic inflammation
- Basic metabolic panel (BMP) – kidney function and electrolytes
- Cystatin C – more accurate kidney marker, particularly if strength training or using creatine
- Urine microalbumin-to-creatinine ratio – early indicator of kidney stress
If you’ve noticed joint stiffness, fatigue, muscle weakness, or changes in balance — this is the conversation to have. You’re not overreacting. You’re paying attention.
When women are invisible in research, they are invisible in care. The gap between what is known and what women are told is not a knowledge problem. It’s a priority problem — and closing it starts with women who know enough to ask better questions.
Read Menopause Musculoskeletal Syndrome (MMS): What Every Woman Should Know →
